STORY CONTINUES BELOW THESE SALTWIRE VIDEOSCOPENHAGEN - Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk, on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million.
The acquisition of Paratek Pharmaceuticals, which was announced in early June, is Novo Holdings' largest individual investment in antimicrobial resistance therapies to date, it said in a statement. Novo Holdings, which controls 76% of the votes in Denmark's Novo Nordisk last week announced a major investment in a new energy transition fund, as it is looking to expand its portfolio beyond health.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: